News
SCPH
4.510
+2.04%
0.090
Weekly Report: what happened at SCPH last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at SCPH last week (0401-0405)?
Weekly Report · 04/08 09:29
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Protara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. Candel Therapeutic shares moved upwards by 25.93% during the session. The company's market cap stands at $236.5 million.
Benzinga · 04/05 12:09
Weekly Report: what happened at SCPH last week (0325-0329)?
Weekly Report · 04/01 09:29
Weekly Report: what happened at SCPH last week (0318-0322)?
Weekly Report · 03/25 09:29
Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 03/19 05:40
Weekly Report: what happened at SCPH last week (0311-0315)?
Weekly Report · 03/18 09:29
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts
ScPharmaceuticals Inc. (NASDAQ:SCPH) just released its latest full-year results. Revenues of US$14m beat forecasts by 2.4%. Statutory losses of US $1.42 per share were smaller than the analysts expected. The analysts are now forecasting revenues of in 2024. The company is expected to grow faster than the wider industry.
Simply Wall St · 03/16 13:12
Buy Rating Affirmed for scPharmaceuticals Amidst Revenue Surge and Solid Financial Footing
TipRanks · 03/15 11:25
scPharmaceuticals Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 03/14 11:33
HC Wainwright & Co. Reiterates Buy on scPharmaceuticals, Maintains $18 Price Target
Benzinga · 03/14 11:23
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)
TipRanks · 03/14 10:20
Strong Buy Recommendation for scPharmaceuticals on Furoscix’s Successful Launch and Growth Prospects
TipRanks · 03/14 00:15
Recap: scPharmaceuticals Q4 Earnings
ScPharmaceuticals reported its Q4 earnings on March 13. The company beat estimates by 17.0%. The company's revenue was up $6.10 million from the same period last year. Last quarter the company missed on EPS by $0.05.
Benzinga · 03/13 20:10
scPharmaceuticals GAAP EPS of -$0.35 beats by $0.07, revenue of $6.1M beats by $0.33M
Seeking Alpha · 03/13 20:06
*ScPharmaceuticals 4Q Rev $6.1M >SCPH
Dow Jones · 03/13 20:02
BRIEF-scPharmaceuticals Q4 Revenue USD 6.096 Million Vs. IBES Estimate USD 5.53 Million
Reuters · 03/13 20:01
*scPharmaceuticals 4Q Loss $13.8M >SCPH
Dow Jones · 03/13 20:01
Press Release: scPharmaceuticals Inc. Reports -2-
In patients with severe symptoms of urinary retention, the administration of furosemide can cause acute urinary retention. The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions. The company is focused on developing and commercializing products to reduce healthcare costs.
Dow Jones · 03/13 20:01
Press Release: scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
ScPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update. Company to host investor conference call and webcast today, March 13, at 4:30pm ET. FUROSCIX revenue of $6.1 million, up 61% sequentially. Company is on track to initiate a pivotal study in the United States.
Dow Jones · 03/13 20:01
More
Webull provides a variety of real-time SCPH stock news. You can receive the latest news about Scpharmaceutical through multiple platforms. This information may help you make smarter investment decisions.
About SCPH
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.